Viral hepatitis is second to gonorrhea as the most commonly reported infectious disease in the US. Hepatitis B accounts for the majority of viral hepatitis cases. Fortunately, the disease is self-limiting and frequently resolves completely with minimal complications; however, a significant number of individuals may experience long-term sequelae. Research utilizing genetic engineering has led to the development of yeast-derived recombinant DNA (YDR) hepatitis vaccines—a significant advancement in the control and prevention of hepatitis B. The recombinant process allows production of unlimited quantities of vaccine at considerably lower cost and without the potential threat of blood-borne illness. Clinical trials in various high-risk populations have demonstrated the effectiveness and safety of YDR vaccines. However, questions regarding optimal regimen and the need for periodic revaccination remain unanswered. Persons at risk should be adequately vaccinated against hepatitis B.
Get full access to this article
View all access options for this article.
References
1.
KaneMAAlterMJHadlerSCMargolisHS. Hepatitis B infection in the United States. Am J Med1989; 87 (suppl 3A): S11–3.
2.
Centers for Disease Control. Protection against viral hepatitis: Recommendations of the Immunization Practices Advisory Committee. MMWR1990; 39 (suppl 2): 1–26.
3.
MaynardJE. Hepatitis B—global importance and need for control. Vaccine1990; 8 (suppl): S18–20.
4.
PastorekJG. Hepatitis B. Obstet Gynecol Clin North Am1989; 16: 645–57.
5.
GillumJEGarrisonNWCrossleyKBRotschaferJC. Current immunization practices. 2. Hemophilus influenzae, pneumococcal, and meningococcal infections, rabies, and hepatitis. Postgrad Med1989; 85: 199–202, 207–10.
6.
SzmunessWPrinceAHirschR., Familial clustering of hepatitis B infection. N Engl J Med1973; 289: 1162–5.
AlterMJHadlerSCMargolisHS. The changing epidemiology of hepatitis B in the United States: Need for alternative vaccination strategies. JAMA1990; 263: 1218–22.
9.
BerlinBS. Viral hepatitis. In: YoumansGPPatersonPYSommersHM, eds. The biologic and clinical basis of infectious diseases. 3rd ed. Philadelphia: WB Saunders, 1985: 538–50.
10.
PerrilloRPSchiffERDavisGL, A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med1990; 323: 295–301.
11.
StephenneJ. Development and production aspects of a recombinant yeast-derived hepatitis-B vaccine. Vaccine1990; 8 (suppl): S69–73.
12.
Product Information. Engerix-B. Philadelphia: Smith Kline and French, 1989.
13.
Product Information. Recombivax HB. West Point, PA: Merck Sharp and Dohme, 1988.
14.
BrugueraMCremadesMRodicioJL, Immunogenicity of a yeast-derived hepatitis B vaccine in hemodialysis patients. Am J Med1989; 87 (suppl 3A): S30–2.
15.
HauserPVoetPSimoenE., Immunological properties of recombinant HBsAg produced in yeast. Postgrad Med J1987; 63 (suppl 2): 83–91.
16.
HauserPThomasHCWatersJ., Induction of neutralizing antibodies in chimpanzees and in humans by a recombinant yeast-derived hepatitis B surface antigen particle. In: ZuckermanAJ, ed. Viral hepatitis and liver disease. New York: Alan R. Liss, 1988: 1031–7.
17.
EminiEAElusRWMillerWJ, Production and immunological analysis of recombinant hepatitis B vaccine. J Infect1986; 13 (suppl A): 3–9.
18.
Kapusnik-UnerJE. Risk of exposure to HIV infection for clinical pharmacists. Am J Hosp Pharm1989; 46 (suppl 3): S14–5.
19.
GoilavCPiotP. Vaccination against hepatitis B in homosexual men: A review. Hosp Form1990; 25 (suppl C): 15–9.
20.
Laukamm-JostenUVon LaerGFeldmeierH., Active immunization against hepatitis B: Immunogenicity of a recombinant DNA vaccine in females, heterosexual and homosexual males. Postgrad Med J1987; 63 (suppl 2): 143–6.
21.
GoilavCPrinsenHPiotP. Protective efficacy of a recombinant DNA vaccine against hepatitis-B in male homosexuals—results at 36 months. Vaccine1990; 8 (suppl): S50–2.
22.
TongMJ. Hepatitis B vaccination of neonates and children. Am J Med1989; 87 (suppl 3A): S33–5.
23.
StevensCETaylorPETongMJ, Yeast-recombinant hepatitis B vaccine: Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA1987; 257: 2612–6.
24.
PoovorawanYSanpavatSPongpunlertW., Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBs antigen-positive mothers. JAMA1989; 261: 3278–81.
25.
CadranelSZeghlacheSFernandezSSafaryAAndreF. Vaccination of newborns of HBsAg-positive carrier mothers with recombinant DNA hepatitis B vaccine. Postgrad Med J1987; 63 (suppl 2): 159–60.
26.
PoovorawanYSanpavatSPongpunlertW., Comparison of a recombinant DNA hepatitis-B vaccine alone or in combination with hepatitis-B immune globulin for the prevention of perinatal acquisition of hepatitis-B carriage. Vaccine1990; 8 (suppl): S56–9.
27.
VandammePVranckxRMeheusA. Immunogenicity of a recombinant DNA hepatitis-B vaccine in institutionalized patients with Downs syndrome. Vaccine1990; 8 (suppl): S52–5.
28.
SeaworthBDruckerJStarlingJ., Hepatitis B vaccines in patients with chronic renal failure before dialysis. J Infect Dis1988; 157: 332–7.
29.
MannucciPMGringeriAMorfiniM., Immunogenicity of a recombinant hepatitis B vaccine in hemophiliacs. Am J Hematol1988; 29: 211–4.
30.
GiammancoGDegrandiVPignatoS., Yeast-derived hepatitis B vaccine in thalassemic patients: A preliminary report. Postgrad Med J1987; 63 (suppl 2): 151–4.
31.
JustMBergerRJustV. Reactogenicity and immunogenicity of a recombinant hepatitis B vaccine compared with a plasma-derived vaccine in young adults. Postgrad Med J1987; 63 (suppl 2): 121–3.
32.
CrovariPCrovariPCPetrilliRCIcardiGCBonanniP. Immunogenicity of a yeast-derived hepatitis B vaccine (Engerix-B) in healthy young adults. Postgrad Med J1987; 63 (suppl 2): 161–4.
33.
ScheiermannNGesemannMMaurerCJustMBergerR. Persistence of antibodies after immunization with a recombinant yeast-derived hepatitis-B vaccine following two different schedules. Vaccine1990; 8 (suppl): S36–40.
34.
WestDJ. Clinical experience with hepatitis B vaccines. Am J Infect Control1989; 17: 172–80.
35.
OdakaNEldredLCohnS., Comparative immunogenicity of plasma and recombinant hepatitis B virus vaccines in homosexual men. JAMA1988; 260: 3635–7.
36.
HeijtinkRAVan Der Velde-LagendijkMAWeberYAM, Hepatitis B vaccination in mentally retarded patients: Recombinant vaccine versus plasma-derived vaccine. In: ZuckermanAJ, ed. Viral hepatitis and liver disease. New York: Alan R. Liss, 1988: 1068–70.
37.
CrovariPCuneo-CrovariPIcardiGCBonanniPCoppolaRC. Immunization of young adults with two yeast-derived hepatitis B vaccines. In: ZuckermanAJ, ed. Viral hepatitis and liver disease. New York: Alan R. Liss, 1988: 1071–3.
38.
Dahl-HansenESiebkeJCFrolandSSDegreM. Immunogenicity of yeast-derived hepatitis B vaccine from two different producers. Epidemiol Infect1990; 104: 143–9.
39.
WeissmanJYTsuchiyoseMMTongMJ, Lack of response to recombinant hepatitis B vaccine in nonresponders to the plasma vaccine. JAMA1988; 260: 1734–8.
40.
BuchbinderSLifsonAHessolN., Should HIV seropositives receive hepatitis B vaccine (abstract)? 29th Interscience Conference on Antimicrobial Agents and Chemotherapy. Houston, TX; September, 1989: 283.
41.
SafaryABosciaJMoonsammyGAndreF. Anti-HBs responses to hepatitis B vaccination in anti-HIV negative and positive homosexual men and parenteral drug users (abstract). 29th Interscience Conference on Antimicrobial Agents and Chemotherapy. Houston, TX; September, 1989: 132.
42.
WeberDJRutalaWAKenyearSALemonSM. Response to deltoid muscle injection of hepatitis B vaccine after failure to respond to gluteal injections (letter). JAMA1986; 255: 2157.
43.
AlperCAKruskallMSMarcus-BagleyD., Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med1989; 231: 708–12.
44.
PuotiCPataneFClapsGD'AnnaC. Ridotta immunogenicita del vaccino anti-epatite B inoculate nel gluteo. Prog Med (Rome)1987; 43: 165–8.
45.
HellgrenTE. Deltoid versus buttock as preferred site of injection for hepatitis B vaccine. J Fla Med Assoc1989; 76: 399–402.
46.
LindsayKLHerbertDAGitnickGL. Hepatitis B vaccine: Low postvaccination immunity in hospital personnel given gluteal injections. Hepatology1985; 5: 1088–90.
47.
JustMBergerRScheiermannN. Persistence of antibodies following vaccination with a yeast-derived recombinant hepatitis B vaccine. Vaccine1988; 6: 401–2.
48.
NommensenFEGoSTMaclarenDM. Half-life of HBs antibody after hepatitis B vaccination: An aid to timing of booster vaccination. Lancet1989; 2: 847–9.
49.
AmbroschFFrisch-NiggemeyerWKremsnerP., Persistence of vaccine-induced antibodies to hepatitis B surface antigen and the need for booster vaccination in adult subjects. Postgrad Med J1987; 63 (suppl 2): 129–35.
50.
AndreFESafaryA. Summary of clinical findings on Engerix-B, a genetically engineered yeast-derived hepatitis B vaccine. Postgrad Med J1987; 63 (suppl 2): 169–78.
51.
AndreFESafaryA. Clinical experience with a yeast-derived hepatitis B vaccine. In: ZuckermanAJ, ed. Viral hepatitis and liver disease. New York: Alan R. Liss, 1988: 1025–30.
52.
BrugueraMRodicioJLAlcazarJM, Effects of different dose levels and vaccination schedules on immune responses to a recombinant DNA hepatitis-B vaccine in haemodialysis patients. Vaccine1990; 8 (suppl): S47–9.
53.
AndreFE. Overview of a 5-year clinical experience with a yeast-derived hepatitis-B vaccine. Vaccine1990; 8 (suppl): S74–8.
54.
MundoFFarcaAGonzalezJ., Assessment of the clinical acceptability and efficacy of recombinant DNA hepatitis-B vaccine. Curr Ther Res1989; 46: 789–92.
55.
RingJ. Exacerbation of eczema by formalin-containing hepatitis B vaccine in a formaldehyde-allergic patient (letter). Lancet1986; 2: 522–3.
56.
StephenneJ. Recombinant versus plasma-derived hepatitis B vaccines: Issues of safety, immunogenicity and cost-effectiveness. Vaccine1988; 6: 299–303.
57.
JilgWSchmidtMDeinhardtF. Vaccination against hepatitis B: Comparison of three different vaccination schedules. J Infect Dis1989; 160: 766–9.
58.
SafaryABosciaJMoonsammyGAndreF. An accelerated dosing schedule of hepatitis B vaccination for those needing rapid protection (abstract). 29th Interscience Conference on Antimicrobial Agents and Chemotherapy. Houston, TX; September, 1989: 133.
59.
BrugueraMRodicioJEsteban-MurR., Anti-HBs responses of two four-dose hepatitis B vaccination schedules in hemodialysis patients (abstract). 29th Interscience Conference on Antimicrobial Agents and Chemotherapy. Houston, TX; September, 1989: 132.
60.
BushLMoonsammyGBosciaJ. Evaluation of initiating a hepatitis B vaccination schedule with one vaccine and completing it with another. Hosp Form1990; 25 (suppl C): 25.
61.
CardinaleV, ed. Drug topics red book. Oradell, NJ: Medical Economics, 1990: 284, 344, 581.
